Matrix metalloproteinases and angiogenesis
Author:
- 1 May 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 11 (3) , 295-299
Abstract
Angiogenesis is a prominent feature of numerous diseases, including cancer and arthritis, and appears to play an important role in kidney disease and hypertension. The matrix metalloproteinases, especially matrix metalloproteinase-2, play a vital role during angiogenesis by degrading the surrounding extracellular matrix and allowing endothelial cell invasion. Membrane type 1 matrix metalloproteinase directly degrades matrix components as well as activating matrix metalloproteinase-2 on the cell surface. The integrin receptors, particularly alpha(v)beta(3), can recruit and possibly activate matrix metalloproteinases to localized microdomains on the cell membrane. This restricts matrix metalloproteinase activity to the pericellular region, preventing excessive matrix degradation which would otherwise impede endothelial invasion. Inhibitors of matrix metalloproteinase activity may actually promote cell invasion by preventing uncontrolled matrix degradation. In addition to degrading the matrix, matrix metalloproteinases produce protein fragments that impede their angiogenic action. These multiple regulatory pathways permit fine control over cell invasion during angiogenesis and provide new, precise strategies for targeting abnormal angiogenesis, through control of matrix metalloproteinase activity.Keywords
This publication has 47 references indexed in Scilit:
- How Matrix Metalloproteinases Regulate Cell BehaviorAnnual Review of Cell and Developmental Biology, 2001
- Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesisThe Journal of Pathology, 2001
- Vascular Endothelial Growth Factor Enhances Glomerular Capillary Repair and Accelerates Resolution of Experimentally Induced GlomerulonephritisThe American Journal of Pathology, 2001
- Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in AngiogenesisArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Angiogenesis in autosomal-dominant polycystic kidney diseaseKidney International, 2001
- Impaired Angiogenesis in the Remnant Kidney ModelJournal of the American Society of Nephrology, 2001
- Impaired Angiogenesis in the Remnant Kidney ModelJournal of the American Society of Nephrology, 2001
- Matrix metalloproteinases in cancer invasion, metastasis and angiogenesisDrug Discovery Today, 2001
- Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertensionThe American Journal of Cardiology, 2001
- Angiogenesis: regulators and clinical applicationsBiochemical Pharmacology, 2001